Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

Desensitization and Tachyphylaxis

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction to: Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer.

Drugs·2020

Same author

Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer.

Drugs·2020

Same author

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2020

Same author

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2019

Same author

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2019

Same author

Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2019

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode

Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode

Published on: October 11, 2024

Torasemide prolonged release.

Katherine A Lyseng-Williamson¹

¹Wolters Kluwer Health, Adis Auckland, New Zealand. demail@adis.co.nz

|July 9, 2009

Summary

Torasemide prolonged release (PR) offers similar blood pressure control to immediate-release (IR) torasemide but with reduced plasma fluctuations. This torasemide PR formulation enhances natriuretic efficiency and provides more consistent diuresis for hypertension management.

Area of Science:

Pharmacology
Nephrology
Cardiology

Background:

Torasemide is a high-ceiling diuretic acting on the loop of Henle.
Immediate-release (IR) formulations can cause plasma concentration fluctuations.
Prolonged-release (PR) formulations aim to improve drug delivery and efficacy.

Purpose of the Study:

To compare the antihypertensive efficacy and tolerability of torasemide prolonged release (PR) versus immediate-release (IR) formulations.
To evaluate the pharmacokinetic and natriuretic differences between torasemide PR and IR.

Main Methods:

A 12-week, randomized, double-blind trial comparing once-daily torasemide PR 5-10 mg to torasemide IR 5-10 mg.
Primary endpoint: change from baseline in sitting diastolic blood pressure.

More Related Videos

Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level

Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[¹⁸F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level

Published on: January 24, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Related Experiment Videos

Last Updated: Jun 21, 2026

Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode

Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode

Published on: October 11, 2024

Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level

Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[¹⁸F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level

Published on: January 24, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Secondary assessments included sitting systolic blood pressure, ambulatory blood pressure monitoring, and tolerability.

Main Results:

Torasemide PR demonstrated similar systemic exposure but slower absorption and lower plasma fluctuations compared to torasemide IR.
Antihypertensive efficacy was noninferior between torasemide PR and IR for sitting diastolic BP.
Torasemide PR showed a greater reduction in daytime systolic BP and improved patient BP control rates.

Conclusions:

Torasemide PR offers comparable antihypertensive efficacy to torasemide IR with improved pharmacokinetic profiles.
The PR formulation provides enhanced natriuretic efficiency and more constant diuresis.
Torasemide PR is well-tolerated, with a similar safety profile to the IR formulation.